Krystal Biotech, Inc. KRYS 深 滬
交易中 10-29 11:29:35 美东时间
189.24
-0.410
-0.22%
華盛通- 最 高189.96
- 今 開187.90
- 成交量 4.19万股
- 最 低 184.5319
- 昨 收 189.65
- 總市值 54.77亿
- 52周最高 207.84
- 市盈率 靜 63.12
- 換手率 0.14%
- 52周最低 122.80
- 委 比 42.86%
- 總股本 2894.30万
- 歷史最高 219.34
- 量 比 0.77
- 振 幅 2.86%
- 歷史最低 8.03
- 每 手 1
- 風險率 19.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Krystal Biotech Unit Launches VYJUVEK In Japan For Treatment Of Dystrophic Epidermolysis Bullosa; VYJUVEK Priced At ¥2,955,232.7 Per Unit In Japan
Krystal Biotech, Inc. today reported that, effective as of October 22, 2025, its wholly owned subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK® (beremagene geperpavec) in Japan for
10-22 21:14
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
快讯 | Krystal Biotech Inc：美国银行环球研究将目标价从182美元上调至255美元
Krystal Biotech Inc : BofA Global Research Raises Price Objective to $255 From ...
10-17 18:29
Krystal Biotech Says It Gets US FDA's Platform Technology Designation For HSV-1 Viral Vector To Treat Neurotrophic Keratitis
PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the
10-14 20:09
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis
Krystal Biotech announced that the FDA granted platform technology designation to its genetically modified HSV-1 viral vector used in KB801, a redosable eye drop gene therapy for treating neurotrophic keratitis. This designation recognizes the reproducibility and scalability of their HSV-1 platform and may help accelerate future product development. KB801 aims to reduce treatment burden by enabling sustained NGF production in the eye, with its sa...
10-14 12:00
What's Driving the Market Sentiment Around Krystal Biotech Inc?
Krystal Biotech Inc's (NYSE:KRYS) short interest as a percent of float has rise...
10-10 21:00
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ: KRYS) has outperformed the market over the past 5 years by 16.54% on an annualized basis producing an average annual return of 31.18%. Currently, Krystal Biotech has a market capitalization of $4.73 billion.
09-26 00:45
Krystal Biotech gets expanded FDA approval for Vyjuvek
Krystal Biotech (NASDAQ:KRYS) announced that the FDA has approved an updated label for its gene therapy, Vyjuvek (beremagene geperpavec). The new approval broadens the patient eligibility for Vyjuvek ...
09-15 23:58
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
The U.S. FDA has updated the label for VYJUVEK, allowing its use for dystrophic epidermolysis bullosa (DEB) patients from birth and enabling patients and caregivers to apply the treatment at home. The update also increases flexibility in wound dressing management, improving convenience without compromising safety. Based on real-world data and studies, the changes reinforce VYJUVEK's role as a flexible and effective gene therapy for DEB, addressin...
09-15 12:00
